Please wait while the formulary information is being retrieved.
DEPO-ESTRADIOL (ESTRADIOL CYPIONATE)
- Female hypogonadism
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic prostate carcinoma
- Primary ovarian failure
5 mg/mL intramuscular oil
- Inject 0.2 milliliter (1 mg) by intramuscular route every 4 weeks
Female hypogonadism
- Inject 0.4 milliliter (2 mg) by intramuscular route once a month
- Inject 0.3 milliliter (1.5 mg) by intramuscular route once a month
Primary ovarian failure
- Inject 0.2 milliliter (1 mg) by intramuscular route every 3 weeks
- Inject 0.2 milliliter (1 mg) by intramuscular route every 4 weeks
- Inject 1 milliliter (5 mg) by intramuscular route every 3 weeks
Vasomotor symptoms associated with menopause
- Inject 0.2 milliliter (1 mg) by intramuscular route every 3 weeks
- Inject 0.2 milliliter (1 mg) by intramuscular route every 4 weeks
- Inject 1 milliliter (5 mg) by intramuscular route every 3 weeks
- Inject 1 milliliter (5 mg) by intramuscular route every 4 weeks
- anastrozole
- Arimidex
- Aromasin
- Cyklokapron
- exemestane
- Femara
- letrozole
- Lysteda
- tranexamic acid
Contraindicated
- None
Severe
Moderate
- A-hydrocort
- A-methapred
- Alagesic Lq
- amobarbital
- Amytal
- Anucort-hc
- Anusol-hc
- Aristospan Intra-articular
- Aristospan Intralesional
- Ascomp With Codeine
- Belladonna-phenobarbital
- betamethasone acet & sod phos
- Bivigam
- Brevital
- budesonide
- Bupap
- butabarbital
- Butalbital Compound W/codeine
- Butalbital Compound-codeine
- butalbital-acetaminop-caf-cod
- butalbital-acetaminophen
- butalbital-acetaminophen-caff
- butalbital-aspirin-caffeine
- Butisol
- Capacet
- Carimune Nf Nanofiltered
- Celestone Soluspan
- Cerebyx
- codeine-butalbital-ASA-caff
- Colocort
- Cortef
- Cortenema
- Cortifoam
- cortisone
- Depo-medrol
- dexamethasone
- Dexamethasone Intensol
- dexamethasone sodium phos (PF)
- dexamethasone sodium phosphate
- Dexpak 10 Day
- Dexpak 13 Day
- Dexpak 6 Day
- Dilantin
- Dilantin Extended
- Dilantin Infatabs
- Dilantin Kapseal
- Dilantin-125
- Donnatal
- Entocort Ec
- Esgic
- ethotoin
- Evista
- Ez Use Joint-tunnel-trigger
- Fioricet
- Fioricet With Codeine
- Fiorinal
- Fiorinal-codeine #3
- First-duke's
- First-mary's Mouthwash
- Flebogamma Dif
- Flo-pred
- fludrocortisone
- fosphenytoin
- Gamastan S/d
- Gammagard Liquid
- Gammagard S-d (iga < 1 Mcg/ml)
- Gammagard S/d
- Gammaked
- Gammaplex
- Gamunex-c
- Grx Hicort 25
- Hemril-30
- Hizentra
- hydrocortisone
- hydrocortisone acetate
- hydrocortisone sod succ (PF)
- hydrocortisone sod succinate
- immune glob(IgG)(hum)-maltose
- immune globulin (human) (IgG)
- immune globulin(hum),capr(IgG)
- Kenalog
- Luminal
- Margesic
- Marten-tab
- Medrol
- Medrol (pak)
- methohexital
- methylprednisolone
- methylprednisolone acetate
- methylprednisolone sod suc(PF)
- methylprednisolone sodium succ
- methylprednisolone-bupivacaine
- Millipred
- Millipred Dp
- Mysoline
- Nembutal Sodium
- nystatin-hydrocortisone-diphen
- nystatin-TCN-HC-diphenhydramin
- Octagam
- Orapred
- Orapred Odt
- Pediapred
- Peganone
- pentobarbital sodium
- phenobarb-hyoscy-atropine-scop
- phenobarbital
- phenobarbital sodium
- Phenytek
- phenytoin
- phenytoin sodium
- phenytoin sodium extended
- Physicians Ez Use M-pred
- prednisolone
- prednisolone acetate
- prednisolone sodium phosphate
- prednisone
- Prednisone Intensol
- primidone
- Privigen
- Proctocort
- raloxifene
- Rayos
- Rectacort-hc
- secobarbital sodium
- Seconal Sodium
- Solu-cortef
- Solu-cortef (pf)
- Solu-medrol
- Solu-medrol (pf)
- Tencon
- triamcinolone acetonide
- triamcinolone hexacetonide
- triamcinolone-lidocaine
- Uceris
- Veripred 20
- Zebutal
- Acute myocardial infarction
- Antithrombin III deficiency
- Carcinoma of breast
- Cerebrovascular accident
- Deep venous thrombosis
- Disease of liver
- Estrogen-dependent neoplasm
- Predisposition to thrombosis
- Protein C deficiency disease
- Pulmonary thromboembolism
- Thromboembolic disorder
- Thrombophilia
Contraindicated
- Bed-ridden
- Coronary artery disease
- Dementia
- Endometrial carcinoma
- Family history of malignant tumor of breast
- Hereditary angioedema
- Hypercalcemia
- Increased cardiovascular event risk
- Invasive surgical procedure
- Malignant neoplasm of the ovary
- Papilledema
- Retinal thrombosis
- Tobacco smoker
Severe
Moderate
- Asthma
- Edema
- Gallbladder disease
- Hepatic porphyria
- Hypertriglyceridemia
- Hypoparathyroidism
- Hypothyroidism
- Migraine
- Seizure disorder
- Systemic lupus erythematosus
- Unspecified lump in breast
- Uterine leiomyoma
DEPO-ESTRADIOL (ESTRADIOL CYPIONATE)
- Female hypogonadism
- Vasomotor symptoms associated with menopause
- Advanced prostatic carcinoma
- Hypoestrogenism due to bilateral oophorectomy
- Metastatic prostate carcinoma
- Primary ovarian failure
- None
- Abdominal distension
- Abdominal pain with cramps
- Anorexia
- Breast milk flow decreased
- Dysmenorrhea
- Gynecomastia
- Mastalgia
- Nausea
- Peripheral edema
- Sinusitis
- Vulvovaginal candidiasis
- Weight gain
More Frequent
Severe
Less Severe
- Endometrial hyperplasia
- Gastroenteritis
- Bronchitis
- Diarrhea
- Dizziness
- Headache disorder
- Libido changes
- Migraine
- Mood changes
- Vaginal discharge
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Acute myocardial infarction
- Cerebrovascular accident
- Change in corneal curvature
- Endometrial carcinoma
- Gallbladder obstruction
- Hepatitis
- Hypertension
- Influenza
- Involuntary muscle movement
- Malignant neoplasm of the ovary
- Neoplasm of breast
- Pulmonary thromboembolism
- Retinal thrombosis
- Thromboembolic disorder
- Thrombotic disorder
- Unspecified lump in breast
- Urticaria
Less Severe
- Abnormal vaginal bleeding
- Amenorrhea
- Back pain
- Body fluid retention
- Chest pain
- Menorrhagia
- Nipple discharge
- Upper respiratory infection
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Estradiol
May cause premature epiphyseal closure. Prepubertal use may induce vaginal bleeding, premature breast development.
- 1 Day – 18 Years
- May cause premature epiphyseal closure. Prepubertal use may induce vaginal bleeding, premature breast development.
Estradiol
- Severity Level:
2
- Additional Notes: Not indicated during pregnancy; no known dev tox
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
Estradiol
Limited data indicate higher excretion may occur w/vaginal vs transderm admin
| General | Excretion Potential | Effect on Infant | Notes |
| Evaluate use carefully | Excreted | Not known; no or inclusive data | Limited data indicate higher excretion may occur w/vaginal vs transderm admin |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
Estrogenic Agents (systemic)
General-Use lowest possible dose for shortest duration and in combination with a progestin as indicated to reduce the risk of endometrial hyperplasia and breast cancer. Cardiovascular-May increase risk for thromboembolic events. Avoid use in patients with known, suspected, or history of arterial or venous thromboembolic disease. Neuro/Psych-May increase the risk for dementia. Genitourinary-May aggravate urinary incontinence.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | Y | Y | N | N |
BEERS: Y HEDIS: Y STOPP: Y
No Known Risk
None
- Estrogens, either used alone or with another hormone (progestin), have rarely caused very serious side effects. Discuss the risks and benefits of hormone treatment with your doctor. Estrogens should not be used to prevent heart disease or dementia.<br /><br /> Estrogens can increase the risk of cancer of the uterus (endometrial cancer). Taking a progestin as directed by your doctor can help decrease this risk. Tell your doctor right away if you have any unusual vaginal bleeding.<br /><br /> In postmenopausal women, estrogens can increase the risk of cancer of the ovaries, stroke, dementia, and serious blood clots in the legs. Estrogens alone do not appear to increase the risk of breast cancer when used for up to 7 years. Estrogen, when used with a progestin, can increase the risk of heart disease (such as heart attacks), stroke, serious blood clots in the lungs/legs, dementia, and cancer of the breast/ovaries.<br /><br /> The risk for serious side effects may depend on the dose of estrogen and the length of time it is used. Therefore, this medication should be used at the lowest effective dose and for the shortest amount of time. Discuss the use of this medication with your doctor regularly (for example, every 3 to 6 months) to see if you still need to use it.<br /><br />If you will be using this medication long-term, you should have regular complete physical exams (for example, once a year) as directed by your doctor. See also Notes section.
| Advanced prostatic carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Female hypogonadism | |
| E28.39 | Other primary ovarian failure |
| Hypoestrogenism due to bilateral oophorectomy | |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| Metastatic prostate carcinoma | |
| C61 | Malignant neoplasm of prostate |
| Primary ovarian failure | |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| Vasomotor symptoms associated with menopause | |
| N95.1 | Menopausal and female climacteric states |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
| 0-9 | A-Z |
|---|---|
| C61 | Malignant neoplasm of prostate |
| C61 | Malignant neoplasm of prostate |
| E28.3 | Primary ovarian failure |
| E28.31 | Premature menopause |
| E28.310 | Symptomatic premature menopause |
| E28.319 | Asymptomatic premature menopause |
| E28.39 | Other primary ovarian failure |
| E28.39 | Other primary ovarian failure |
| E89.4 | Postprocedural ovarian failure |
| E89.40 | Asymptomatic postprocedural ovarian failure |
| E89.41 | Symptomatic postprocedural ovarian failure |
| N95.1 | Menopausal and female climacteric states |
| N95.9 | Unspecified menopausal and perimenopausal disorder |
Formulary Reference Tool